Last Friday, 7h of November 2014, the FDA approved the MannKind’s Afrezza (insulin human) inhalation powder. The product will improve glycemic control in adult patients with diabetes mellitus. The treatment is delivered to the body with an inhaler and is administered at the beginning of a meal. The insulin dissolves into the blood stream quicker than traditional treatments after it enters the lung. This product will still be used in addition to long-acting insulin.
CEO Alfred Mann, keynote presenter at the 2014 Drug Delivery Partnerships event, stated, “Approval of Afrezza is an important milestone for MannKind, as [the] FDA action validates the years of clinical research and commitment that powered the development of this unique therapy….We are excited for patients, as we believe that Afrezza’s distinct profile and non-injectable administration will address many of their unmet needs for mealtime insulin therapy, and has the potential to change the way that diabetes is treated. “
Comentarios recientes